# OnCo record cll-relapsed (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cll-relapsed/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cll-relapsed" ;
  schema:name "Relapsed or refractory chronic lymphocytic leukaemia"@en ;
  schema:alternateName "Relapsed CLL"@en, "Refractory CLL"@en, "Double-refractory CLL (after BTK and BCL-2 inhibitors)"@en, "CLL after BTK inhibitor failure"@en ;
  schema:description "When chronic lymphocytic leukaemia returns, the usual move is to switch drug class: venetoclax-based therapy after a BTK inhibitor, or a BTK inhibitor after venetoclax. Pirtobrutinib (BRUIN) works after the older BTK inhibitors fail, and CAR-T is approved for patients who have run out of both classes."@en ;
  schema:url <https://onco.cc/cancers/cll-relapsed/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/flow-cytometry-mrd/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/>, <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/umrd/>, <https://onco.cc/terms/richter-transformation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/> ;
  onco:pipeline <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/nemtabrutinib/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/trials/bellwave-011/>, <https://onco.cc/trials/cadance-304/> ;
  onco:standardOfCare <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/trials/bruin-cll-321/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/alpine/>, <https://onco.cc/trials/resonate/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/trials/transcend-cll-004/>, <https://onco.cc/drugs/idelalisib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/nemtabrutinib/>, <https://onco.cc/technologies/allogeneic-hsct/> .